incretin and glp-1 Frontiers Incretins as Multi–Disease State Treatments

The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY

Medicaid coverage for weight loss medications varies by state

Hum Behav Emerg Technol

Bain MA et al

Applied warm, theyre ideal for tired legs and poor circulation

If it is tied to weight management, plan for documentation requests and check your plans exclusions in writing before paying